SEATTLE, Jan. 5 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. announced today that Dr. Bruce L.A. Carter, Ph. D., President and Chief Executive Officer, will provide an overview of company activities at the 24th Annual JPMorgan Healthcare Conference in San Francisco on January 11 at 9:00 a.m. Pacific Time. The Company will also discuss preliminary findings from a Phase 1b clinical trial with TACI-Ig in patients with rheumatoid arthritis (RA).
A live audio webcast of the presentation can be accessed by going to: www.zymogenetics.com. The webcast will be archived until February 15th.
About ZymoGenetics
ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2004. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
Contact Investor Relations John Calhoun, MD, MBA Director, Corporate Communications & Investor Relations (206) 442-6744 Media Relations Susan W. Specht, MBA Corporate Communications Manager (206) 442-6592
ZymoGenetics, Inc.CONTACT: investors, John Calhoun, MD, MBA, Director, CorporateCommunications & Investor Relations, +1-206-442-6744, or media, Susan W.Specht, MBA, Corporate Communications Manager, +1-206-442-6592, both ofZymoGenetics, Inc.
Web site: http://www.zymogenetics.com/
